News

Discover the latest STENTYS news.

  • 2018

     

    21/02/2018

    STENTYS launches a €11.8 million rights issue to finance the acquisition of MINVASYS
     

    30/01/2018

    STENTYS announces plans to acquire MINVASYS
     
  • 2017

     

    27/07/2017

    STENTYS Completes Enrollment of the TRUNC Study
     

    24/05/2017

    Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes
     

    03/04/2017

    STENTYS is strengthening its Board by co-opting two new independent members
     
  • 2016

     

    19/07/2016

    STENTYS Enrolls First Patient in Left Main Clinical Trial
     

    04/07/2016

    STENTYS: Appointment of Cardiovascular Device Veteran as New CEO
     

    08/06/2016

    STENTYS Announces CE Marking of its longest Xposition stent
     

    21/03/2016

    STENTYS Announces the CE Marking of the Self-Apposing Stent for Left Main Coronary Artery Disease
     

    29/02/2016

    Results of Self-Apposing Sirolimus-Eluting Stent Trial Published in EuroIntervention
     

    08/02/2016

    Launch of the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication
     

    28/01/2016

    STENTYS: First Intervention with the Self-Apposing Drug-Eluting Stent for Lower Limbs broadcasted live at LINC international congress
     
  • 2015

     

    09/12/2015

    Enrollment Completion of MiStent Randomized Trial against Xience
     

    12/10/2015

    STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years
     

    28/09/2015

    STENTYS Receives CE Mark for Self-Apposing Stent in Lower Limb Artery Disease
     

    19/05/2015

    First Clinical Experience with Xposition shows 100% implantation success, Confirms Ease of Use
     

    28/04/2015

    STENTYS’ Next-Generation of Self-Apposing Stent System Receives CE Marking Ahead of Plan
     

    23/02/2015

    Results of largest STENTYS Stent Trial in Myocardial Infarction Published in EuroIntervention
     

    12/02/2015

    New Self-Apposing Stent Study in Left Main Coronary Artery
     

    28/01/2015

    STENTYS Expands Benefits of First Drug-Eluting, Self-Expanding Stent to Lower Limb Artery Disease
     
  • 2014

     

    03/11/2014

    STENTYS enrichit son offre de produits à toutes les indications coronaires par un accord exclusif avec Micell pour distribuer son stent actif innovant
     

    27/10/2014

    STENTYS’ Sirolimus-Eluting Stent Receives CE Marking
     

    20/10/2014

    STENTYS Wins Large Regional Tender in Middle East
     

    25/09/2014

    STENTYS Adds Branch Office in Dubai
     

    16/09/2014

    STENTYS Stent continues to show low mortality two years after treatment of a heart attack
     

    03/09/2014

    STENTYS Reaches 10,000 Self-Apposing Stent implantations
     

    31/07/2014

    STENTYS Reallocates Resources to focus on its Advanced Drug-Eluting Stent Progra
     

    09/07/2014

    STENTYS Expands Marketing of the Self-Apposing Stent in South America
     

    04/06/2014

    STENTYS to Acquire Stent Delivery Technology for Its Next-Generation of Self-Apposing Stents
     

    27/05/2014

    STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference
     

    20/05/2014

    STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients
     

    07/05/2014

    STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis
     

    29/04/2014

    STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology
     

    10/04/2014

    STENTYS appoints Medical Device Executive to its Board of Directors
     

    08/01/2014

    STENTYS Expands Marketing of its Stents in Asia
     
  • 2013

     

    30/10/2013

    STENTYS Self-Apposing Stent performs well in new coronary indications
     

    29/10/2013

    STENTYS Sirolimus-eluting stent demonstrates faster arterial healing than conventional drug-eluting stent
     

    21/10/2013

    STENTYS to Present first results of Sirolimuseluting Self-Apposing® Stent at TCT Conference
     

    10/07/2013

    STENTYS Self-Apposing Stent Approved in Europe for Additional Coronary Indications
     

    22/05/2013

    Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results
     

    20/05/2013

    STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
     

    09/03/2013

    STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
     

    26/02/2013

    STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13
     

    03/01/2013

    STENTYS clinical study demonstrating superiority of SelfApposing® stents over conventional stents published in American College of Cardiology journal
     
  • 2012

     

    22/10/2012

    STENTYS Receives FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent
     

    22/10/2012

    STENTYS Self-Apposing® Stent continues to demonstrate low mortality at one year in APPOSITION III trial
     

    15/10/2012

    STENTYS to Present One-Year Interim Results From APPOSITION III Study at TCT Conference
     

    26/09/2012

    STENTYS Launches New Stent-Delivery System to Facilitate Implantation in More Complex Vessel Anatomies
     

    14/06/2012

    STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent
     

    16/05/2012

    STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high risk heart attack patients
     

    14/05/2012

    STENTYS expands its product offerings for treating heart attacks
     

    26/03/2012

    STENTYS Self-Apposing technology supported by breaking new scientific evidence
     

    08/02/2012

    Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications
     

    01/02/2012

    STENTYS concludes clinical trial ahead of plan
     
  • 2011

     

    08/11/2011

    Outstanding interim results of STENTYS international clinical study of 600 heart attack patients
     

    12/10/2011

    STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks
     

    21/09/2011

    STENTYS compeltes enrollement of APPOSITION III study for its Self-Apposing Stent to Treat Heart Attacks
     

    15/09/2011

    Over 1000 patients have benefited from STENTYS Self-Apposing technology
     

    31/08/2011

    STENTYS reports six-month 2011 Financial results
     

    26/07/2011

    Revenues for the 1 half of 2011
     

    20/06/2011

    Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board
     

    08/06/2011

    STENTYS recruits Country Managers for France and Italy
     

    18/05/2011

    STENTYS joins Stent for Life Initiative to expand optimal heart attack treatment across Europe
     

    16/05/2011

    Stenting in STEMI: Does Size Matter?
     

    02/05/2011

    STENTYS enrolls first 250 patients, half of Apposition III study of its Self-Apposing Stent for treatment of Heart Attacks
     

    17/03/2011

    STENTYS expands operations into four additional European countries
     

    23/02/2011

    Increased reimbursement of STENTYS drug-eluting stent in Germany
     
  • 2010

     

    09/12/2010

    STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks
     

    23/11/2010

    STENTYS appoints Michel Darnaud to its Board of Directors
     

    15/09/2010

    Stentys discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent
     

    10/09/2010

    Stentys self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction
     

    09/09/2010

    Stentys completes enrollment in clinical study of its breakthrough stent to treat Acute Myocardial Infarction
     

    02/09/2010

    Stentys appoints Stanislas Piot as Chief Financial Officer
     

    05/05/2010

    Stentys drug-eluting self-expanding stent receives CE Marking
     

    05/03/2010

    Stentys self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS)
     

    07/02/2010

    Stentys drug-eluting self-expanding coronary stent shows 4% restenosis in complex lesions
     
  • 2009

     

    01/12/2009

    First patient enrolled in randomized study of STENTYS self-expanding stent vs. conventional stent to treat acute myocardial infarction (AMI).
     

    31/10/2009

    STENTYS expands Scientific Advisory Board (SAB) on heels of reporting successful clinical trial results for world’s first self-expanding stent to treat AMI.
     

    15/09/2009

    STENTYS discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent.
     

Page ID 1288   |   Last edited 2018/05/04